Virchow Biotech

Hyderabad, India Founded: 2000 • Age: 26 yrs
Recombinant biologicals for wound care and bone disorders are developed.
Annual revenue $68.8M Latest available
Total funding - Funding intelligence
Employees 1048 Tracked headcount
Investors - Known backers
Products 5 Services tracked
Competitors - Brand Intelligence

About Virchow Biotech

Virchow Biotech is a company based in Hyderabad (India) founded in 2000. The company has 1,048 employees as of April 07, 2024. Virchow Biotech offers products and services including SCARAZE, CADEXOMER IODINE, LEUPROLIDE ACETATE, ULINASTATIN, and Bifidobacterium bifidum.

  • Headquarter Hyderabad, India
  • Employees 1048 as on 07 Apr, 2024
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Legal Name Virchow Biotech Private Limited
  • Date of Incorporation 04 Apr, 2001
  • Jurisdiction \Hyderabad-55, Telangana, India
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $68.82 M (USD)
    -0.86
    as on Mar 31, 2023
  • Net Profit
    $8.58 M (USD)
    -20.99
    as on Mar 31, 2023
  • EBITDA
    $16.08 M (USD)
    -2.63
    as on Mar 31, 2023
  • Latest Funding Round
    Not available
  • Investors
    Not available
  • Employee Count
    1048

    as on Apr 07, 2024

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Virchow Biotech

Virchow Biotech offers a comprehensive portfolio of products and services, including SCARAZE, CADEXOMER IODINE, LEUPROLIDE ACETATE, ULINASTATIN, and Bifidobacterium bifidum.

Product name locked
Category locked
Primary

Product for wound healing and scar reduction.

Product name locked
Category locked
Locked

Antiseptic for wound care applications.

Product name locked
Category locked
Locked

Hormone treatment for gynecological conditions.

Product name locked
Category locked
Locked

Protease inhibitor for urological treatments.

Product name locked
Category locked
Locked

Probiotic strain for digestive health support.

People of Virchow Biotech

Headcount 500-1000
Employee Profiles 2
Employee Profiles
People
Amol Tungenwar
Senior Executive

Unlock access to complete

Teams

Unlock access to complete

Funding Insights of Virchow Biotech

Premium access

Detailed funding history for Virchow Biotech

Round names, dates, amounts, investors, and valuation history require an active premium plan.

  • Round names and dates
  • Funding amounts
  • Participating investors
  • Valuation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Virchow Biotech

Investments
Premium access

Investment portfolio details for Virchow Biotech

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Virchow Biotech

Premium access

Detailed financials for Virchow Biotech

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Virchow Biotech Comparisons

Virchow Biotech Primary company
Description
Recombinant biologicals for wound care and bone disorders ar...
Location
Hyderabad, India
Founded Year
2000
Annual Revenue
$68.82 M (USD)
Net Profit
$8.58 M (USD)
EBITDA
$16.08 M (USD)
Employees
1,048
As of 2024
Premium access

Peer comparison for Virchow Biotech

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Virchow Biotech

Premium access

Detailed competitors of Virchow Biotech

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Virchow Biotech

Premium access

Complete news archive for Virchow Biotech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Virchow Biotech

Virchow Biotech was founded in 2000.

Virchow Biotech is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Ravi Kumar Gattupalli is the current CEO of Virchow Biotech.

As of Apr 07, 2024, the latest employee count at Virchow Biotech is 1,048.

Annual revenue of Virchow Biotech is $68.82M as on Mar 31, 2023.

Virchow Biotech is focussed developing biologicals and biogeneric products. It is focussed on the development of products based on recombinant DNA and molecular biology. It developed two bio-generic human therapeutics, Healace (rh PDGF-BB, marketed in India as Plermin by Dr. Reddys) and Osteotide (marketed in India as Bonista by Ranbaxy). Its product portfolio consists of 15 bio-generic products covering wound care and haemostasis, ophthalmology, orthopedics, probiotics and gastroenterology. It also has five other recombinant bio-generics in the pipeline. It is filing for US FDA approval for its developed advanced wound care products and has received Drug controls (DCGI) approval for conducting clinical trials on periogen, a recombinant therapeutic product for periodontal diseases.

Virchow Biotech offers SCARAZE, CADEXOMER IODINE, LEUPROLIDE ACETATE, ULINASTATIN, and Bifidobacterium bifidum.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available